logo
Plus   Neg
Share
Email

Novartis Pharma Announces Simultaneous Approval Of Five New Products In Japan

Novartis Pharma K.K. announced that Japanese Ministry of Health, Labour and Welfare has issued simultaneous approval for the company's five new products. Tabrecta, an oral MET inhibitor for MET exon 14 skipping mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer, was approved. The other approved products are: Entresto in chronic heart failure, Mayzent in secondary progressive MS, Enerzair and
Atectura in different forms of asthma.

Kazunari Tsunaba, Representative Director and President of Novartis Pharma, said: "All five medicines are truly novel and transformative treatments and therefore mark an important milestone in our mission to reimagine medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Amazon.com, Inc. can be held liable for damages caused by defective goods sold on its Marketplace including third parties, according to a ruling by a California appeals court. The California Fourth District Court of Appeals was pronouncing the ruling in a case where a defective replacement laptop battery caught fire and inflicted a woman with third-degree burns. Facebook has launched "Voting Information Center" on Facebook and Instagram platforms, with a view to boosting the number of Americans vote in the upcoming U.S. presidential election in November. The social media giant's latest initiative is expected to help 4 million voters register this year, and help them navigate a 'confusing election process'. Epic Games Inc., the developer of popular game Fortnite, has filed lawsuits against both Apple Inc. and Google after they removed the game from their app stores. The development reflects disputes related to app store fee the tech giants take from each purchase. Epic Games, which has been against the 30 percent revenue cut the two tech giants take from paid apps, added a direct payment option.
Follow RTT